Filing Flows › AstraZeneca (AZN) › Capital expenditures
AstraZeneca (AZN) capital expenditures by quarter
AstraZeneca's capital expenditures were $676M in Q3 2026 (third quarter 2026), -11% from Q2 2026. Over the last 4 quarters it ranged from $547M (Q1 2026) to $763M (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $676M | -11% | -1% |
| Q2 2026 | $763M | +39% | — |
| Q1 2026 | $547M | -20% | — |
| Q3 2025 | $686M | — | — |
Q3 2026 at a glance
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
Questions
What is AstraZeneca's capital expenditures?
AstraZeneca's capital expenditures were $676M in Q3 2026 (third quarter 2026), -11% from Q2 2026.
How has AstraZeneca's capital expenditures changed?
Over the last 4 quarters it ranged from $547M (Q1 2026) to $763M (Q2 2026).